PRQR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

6.09M

+25.53%

-0.117

+18.65%

5.53M

+3.38%

-0.139

+28.64%

5.10M

+10.26%

-0.140

+0.59%

Estimates Revision

The market is revising Downward the revenue expectations for ProQR Therapeutics N.V. (PRQR) for FY2025, with the revenue forecasts being adjusted by -20.86% over the past three months. During the same period, the stock price has changed by -25.00%.

Revenue Estimates for FY2025

Revise Downward

-20.86%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.14%

In Past 3 Month

Stock Price

Go Down

-25.00%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast PRQR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRQR is 7.25 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

4.00

Averages

7.25

High

12.00

Current: 0.000

Low

4.00

Averages

7.25

High

12.00

Evercore ISI

Outperform

maintain

$4 -> $5

2025-07-11

Reason

Evercore ISI

Price Target

$4 -> $5

2025-07-11

maintain

Outperform

Reason

Evercore ISI raised the firm's price target on ProQR Therapeutics to $5 from $4 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a "notable lengthening" of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.

Oppenheimer

Andreas Argyrides

Outperform

downgrade

$15 -> $9

2025-05-13

Reason

Oppenheimer

Andreas Argyrides

Price Target

$15 -> $9

2025-05-13

downgrade

Outperform

Reason

Oppenheimer analyst Andreas Argyrides lowered the firm's price target on ProQR Therapeutics to $9 from $15 and keeps an Outperform rating on the shares following quarterly results. The firm notes lead program/AX-0810 for cholestatic diseases remains on track for a 2Q25 CTA submission followed by topline data in Q4 2025 from the healthy volunteers study. Oppenheimer expects clinical candidate selection in 2025 for AX-2402/Rett Syndrome and AX-2911/MASH followed by trial initiations and topline readouts in 2026. The firm sees ProQR's initial clinical data and 2025 RNA editing catalysts re-igniting investor interest. While its fundamental outlook remains intact, negative sector sentiment continues to weigh heavily on early clinical-stage companies with no clinical data, as such, Oppenheimer increases the discount rate from 30% to 40%.

HC Wainwright & Co.

Andrew Fein

Strong Buy

Maintains

$10 → $12

2025-03-14

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$10 → $12

2025-03-14

Maintains

Strong Buy

Reason

Chardan Capital

Keay Nakae

Strong Buy

Maintains

2025-03-14

Reason

Chardan Capital

Keay Nakae

Price Target

2025-03-14

Maintains

Strong Buy

Reason

Jones Trading

Catherine Novack

Strong Buy

Initiates

$11

2025-02-12

Reason

Jones Trading

Catherine Novack

Price Target

$11

2025-02-12

Initiates

Strong Buy

Reason

JonesResearch analyst Catherine Novack initiated coverage of ProQR Therapeutics with a Buy rating and $11 price target. The firm says the company brings more than a decade of experience in RNA therapeutics, emerging as a pure-play RNA editing biotech with early-stage programs in both rare disease and more prevalent indications such as liver and cardiovascular disease. The analyst is bullish on the "burgeoning" RNA editing space, believing it to be safer and more versatile than DNA editing, and therefore more broadly applicable.

Valuation Metrics

The current forward P/E ratio for ProQR Therapeutics NV (PRQR.O) is -3.67, compared to its 5-year average forward P/E of -5.16. For a more detailed relative valuation and DCF analysis to assess ProQR Therapeutics NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.16

Current PE

-3.67

Overvalued PE

-2.55

Undervalued PE

-7.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.79

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.50

Undervalued EV/EBITDA

-4.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

74.61

Current PS

9.77

Overvalued PS

241.37

Undervalued PS

-92.16

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PRQR News & Events

Events Timeline

No data

News

5.0

2025-11-24NASDAQ.COM

Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading

9.0

2025-10-23NASDAQ.COM

VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements

9.0

2025-10-20Newsfilter

ProQR Secures CTA Approval for AX-0810 and Plans Virtual Investor and Analyst Event on November 3, 2025

People Also Watch

Frequently Asked Questions

What is ProQR Therapeutics NV (PRQR) stock price today?

The current price of PRQR is 1.875 USD — it has decreased -10.71 % in the last trading day.

What is ProQR Therapeutics NV (PRQR)'s business?

ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).

What is the price predicton of PRQR Stock?

What is ProQR Therapeutics NV (PRQR)'s revenue for the last quarter?

ProQR Therapeutics NV revenue for the last quarter amounts to 2.92M USD, decreased -26.78 % YoY.

What is ProQR Therapeutics NV (PRQR)'s earnings per share (EPS) for the last quarter?

ProQR Therapeutics NV. EPS for the last quarter amounts to -0.10 USD, decreased -0.00 % YoY.

What changes have occurred in the market's expectations for ProQR Therapeutics NV (PRQR)'s fundamentals?

How many employees does ProQR Therapeutics NV (PRQR). have?

ProQR Therapeutics NV (PRQR) has 166 emplpoyees as of January 09 2026.

What is ProQR Therapeutics NV (PRQR) market cap?

Today PRQR has the market capitalization of 221.22M USD.